200,000 Shares in Axon Enterprise, Inc $AXON Acquired by Styrax Capital LP

Styrax Capital LP acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the first quarter, HoldingsChannel reports. The institutional investor acquired 200,000 shares of the biotechnology company’s stock, valued at approximately $84,938,000. Axon Enterprise accounts for approximately 5.9% of Styrax Capital LP’s investment portfolio, making the stock its 9th biggest position.

Other institutional investors have also recently made changes to their positions in the company. Evergreen Capital Management LLC boosted its stake in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the period. Synergy Financial Group LTD grew its holdings in shares of Axon Enterprise by 1.4% in the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after purchasing an additional 19 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after buying an additional 19 shares in the last quarter. Certuity LLC grew its position in Axon Enterprise by 5.1% in the fourth quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 23 shares in the last quarter. Finally, Pure Financial Advisors LLC boosted its holdings in shares of Axon Enterprise by 6.7% in the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the sale, the executive owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares of the company’s stock, valued at $82,609,106.25. This trade represents a 7.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 58,989 shares of company stock valued at $30,527,983 in the last 90 days. 4.20% of the stock is owned by insiders.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $502.34 on Monday. The firm’s 50 day moving average price is $483.26 and its 200-day moving average price is $478.81. The company has a market cap of $40.49 billion, a P/E ratio of 201.74, a PEG ratio of 10.25 and a beta of 1.38. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same quarter in the prior year, the business posted $1.47 EPS. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. On average, sell-side analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on AXON shares. Citizens Jmp reiterated a “market outperform” rating and set a $700.00 price target on shares of Axon Enterprise in a report on Thursday, June 25th. Royal Bank Of Canada reissued an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Needham & Company LLC upped their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Barclays reduced their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Fifteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $725.25.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.